of the economic burden and the
survival rate of deeply premature babies. Design
ATAS, A.E.,
SARAC, A.,
DIRICAN, A.,
TOPBASI, N.,
UZAR, T.,
RASTGAR, L.,
PANKINA, E.,
OZKAYA, S. (2019) was administered during cardiopulmonary resuscitation in
18% (n = 13) of patients. The
survival rate was 30.7% (n
Survival of patients with lymphoproliferative diseases increases.
For effective treatment we should